ProKidney Corp
PROK1.870USD
+0.140+8.09%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
254.28MMarket Cap
LossP/E TTM
More Details of ProKidney Corp Company
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
ProKidney Corp Info
Ticker SymbolPROK
Company nameProkidney Corp
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Number of employees204
Security typeOrdinary Share
Fiscal year-endJun 30
Address2000 Frontis Plaza Blvd
CityWINSTON-SALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27103
Phone13369997028
Websitehttps://prokidney.com/
Ticker SymbolPROK
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Company Executives of ProKidney Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Other
60.77%
Shareholders
Shareholders
Proportion
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Other
60.77%
Shareholder Types
Shareholders
Proportion
Corporation
23.56%
Hedge Fund
11.04%
Investment Advisor
10.26%
Investment Advisor/Hedge Fund
6.12%
Individual Investor
1.83%
Research Firm
0.90%
Endowment Fund
0.71%
Bank and Trust
0.04%
Family Office
0.02%
Other
45.52%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
178
41.07M
29.01%
-2.81M
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tolerantia LLC
22.62M
15.98%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
8.72%
--
--
Sep 30, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.58%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
6.41M
4.53%
+698.99K
+12.24%
Sep 30, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.42%
--
--
Oct 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.73%
--
--
Nov 30, 2025
Bleichroeder LP
2.00M
1.41%
--
--
Sep 30, 2025
Millennium Management LLC
1.96M
1.38%
+1.96M
--
Sep 30, 2025
The Vanguard Group, Inc.
1.56M
1.1%
-3.75K
-0.24%
Sep 30, 2025
Culleton (Bruce)
1.54M
1.09%
+1.54M
--
Mar 17, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
Schwab U.S. Small-Cap ETF
Proportion0.01%
ALPS Medical Breakthroughs ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
